[56] reported that DDR1 expression was significantly higher in dry eye corneas than in normal controls and that DDR1‐IN‐1 (a DDR1 inhibitor) treatment could improve dry eye symptoms by decreasing lipid hydroperoxide levels and inhibiting the expression of ferroptosis markers, particularly ACSL4. The gene discussed is ACSL4; the disease is dry eye syndrome.